🟢 Context Therapeutics is trading 5% up in after-hours trading

Context Therapeutics is trading at $0.29, up 5.20% in after-hours trading; no clear company-specific catalyst was identified for the October 13 gain.

• The latest located company release was the September 9 announcement that the first patient had been dosed in the CT-202 Phase 1 trial.
• Reporting said the regular-session decline lacked a clear company-specific catalyst; broad market indices were nearly flat, and neither explains the after-hours rise. The move may reflect after-hours trading activity, but available evidence does not establish its cause.